Annual Drug Patent Expirations for VICTOZA Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug and
covering the Victoza formulation. These patents generally expire Victoza, liraglutide. Ozempic, semaglutide. Rybelsus, oral
patent expiration imperative to fiscal survival. In worst-case Victoza, loses patent protection next year. Novo is approaching
Victoza's patents have been open to challenges since 17 December, 2024. Based on its patents and exclusivities, its generic launch date is estimated to be . Details of Victoza's patents and their expiration are given in the table below. Download patent list as spreadsheet.
The semaglutide patent is expected to expire in early 2024. Liraglutide's (Victoza) patent protection has already expired in 2024, and
Good news for people with metabolic syndrome: The patent for liraglutide in the name of Victoza by NOVO NORDISK INC is expiring in December
With the first patent for Victoza expiring in August and subsequent patent expirations for this drug drawing closer, research Victoza Patent Expiration.
Generic Victoza, produced by Teva Pharmaceuticals, is the first GLP-1 RA that has gone generic. Victoza's patent in the US and Europe expired in late 2024
Victoza or the injection device with torsion spring and patent for semaglutide, Ozempic's active ingredient, expires. Contra.
Comments
Sometimes marriages do go on past their expiration date.